Table 2.
Predictors of GPR30 Expression in LMP Tumors and Epithelial Ovarian Cancer (EOC).
| LMP tumors (45) | EOC (89) | Totals (134) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | GPR30 High N (%) | GPR30 Low N (%) | Fisher P | GPR30 High N (%) | GPR30 Low N (%) | Fisher P | GPR30 High N (%) | GPR30 Low N (%) | Fisher P |
| Age | 0.46 | 0.18 | 0.02 | ||||||
| ≤ 50 yrs | 4 (15.4) | 22 (84.6) | 10 (37.0) | 17 (63.0) | 14 (26.4) | 39 (73.6) | |||
| >50 yrs | 5 (26.3) | 14 (73.7) | 33 (53.2) | 29 (46.8) | 38 (46.9) | 43 (53.1) | |||
| Histology | 0.46* | 0.58 | 0.20 | ||||||
| Serous | 6 (27.3) | 16 (72.7) | 22 (43.1) | 29 (56.9) | 28 (38.4) | 45 (61.6) | |||
| Mucinous | 3 (13.6) | 19 (86.4) | 8 (53.3) | 7 (46.7) | 11 (29.7) | 26 (70.3) | |||
| Endometrioid | 0 | 1 (100.) | 7 (50.0) | 7 (50.0) | 7 (46.7) | 8 (53.3) | |||
| Other | 0 | 0 | 6 (66.7) | 3 (33.3) | 6 (66.7) | 3 (33.3) | |||
| Tumor Grade | NA | 0.08 | 0.003 | ||||||
| 0 | 9 (20.0) | 36 (80.0) | NA | NA | 9 (20.0) | 36 (80.0) | |||
| 1 | 4 (30.8) | 9 (69.2) | 4 (30.8) | 9 (69.2) | |||||
| 2 | 9 (40.9) | 13 (59.1) | 9 (40.9) | 13 (59.1) | |||||
| 3 | 30 (55.6) | 24 (44.4) | 30 (55.6) | 24 (44.4) | |||||
| FIGO Stage | 0.26** | 0.01 | < 0.001 | ||||||
| I | 7 (17.5) | 33 (82.5) | 7 (29.2) | 17 (70.8) | 14 (21.9) | 50 (78.1) | |||
| II | 2 (66.7) | 1 (33.3) | 2 (22.2) | 7 (77.8) | 4 (33.3) | 8 (66.7) | |||
| III | 0 | 2 (100.) | 24 (55.8) | 19 (44.2) | 24 (53.3) | 21 (46.7) | |||
| IV | 0 | 0 | 10 (76.9) | 3 (23.1) | 10 (76.9) | 3 (23.1) | |||
GPR30 High, expression above the median (80).
*
In order to compute differences in LMP tumors, rows with 0 values were deleted and the single endometrioid was included with serous for analysis by histology.
**
LMP Stage I (40 cases) was compared with LMP II + III (5 cases) in the analysis by stage of disease; NA, not applicable.